QT Imaging Holdings (QTI) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
25 Mar, 2026Technology and innovation
Developed a 3D breast imaging device using quantitative transmission imaging, cleared by the FDA for both transmission and reflection ultrasonic imaging of the breast.
Technology offers high-resolution, no-radiation, painless scans, with diagnostic performance comparable to MRI but at lower cost and greater accessibility.
Platform integrates proprietary hardware, advanced image reconstruction software, and AI-powered clinical decision tools for precision in breast health.
Generates quantitative biomarkers (speed of sound, attenuation, reflection) for objective, reproducible tissue characterization and AI-driven analysis.
Cloud-based SaaS platform enables automated image analysis, lesion segmentation, and continuous learning from clinical data.
Clinical and patient impact
Provides a comprehensive, operator-independent imaging solution suitable for women with dense breasts, implants, or those under 40 not eligible for mammography.
Reduces patient anxiety, scheduling complexity, and unnecessary interventions by offering a one-stop, painless, and efficient exam.
Demonstrated higher diagnostic accuracy in dense breasts, identifying abnormalities missed by mammograms in 84% of cases in a mini-study.
Enables early detection, therapy monitoring, and personalized medicine through quantitative imaging biomarkers.
Supported by $18 million in NIH funding for supplemental imaging in women with dense breasts.
Business model and partnerships
Operates a hybrid hardware and SaaS model, with recurring revenue from cloud-based analytics and biomarker services.
Strategic distribution agreements in the USA (NXC Imaging/Canon), Saudi Arabia (Gulf Medical), and UAE (Al Naghi Medical), with committed minimum order quantities through 2028.
Manufacturing partnership with Canon Medical Systems.
Projected $39 million in 2026 contracted revenue from USA, Saudi Arabia, and UAE.
Expanding clinical footprint with installations at major centers including Mayo Clinic, NIH, and commercial imaging centers.
Latest events from QT Imaging Holdings
- Q3 2025 revenue up 339% to $4.2M, net loss widened, and 2026 outlook raised to $39M.QTI
Q3 202522 Apr 2026 - $2.56M PIPE financing and $1.0M Q3 revenue support liquidity amid ongoing commercialization.QTI
Q3 202422 Apr 2026 - Q2 2024 revenue hit $1.7M with 51% margin; net loss widened to $6.4M amid higher costs.QTI
Q2 202422 Apr 2026 - Q1 2025 revenue doubled to $2.8M with 65% margin; net loss widened to $11.1M.QTI
Q1 202522 Apr 2026 - Q2 revenue doubled to $3.7M, net loss widened, liquidity boosted by new financings.QTI
Q2 202522 Apr 2026 - 2025 revenue hit $18.9M, with 2026 guidance at $39M on SaaS and distribution momentum.QTI
Q4 202522 Apr 2026 - 2024 revenue surged to $4.9M with 54% gross margin; 2025 revenue forecast at $18M.QTI
Q4 202422 Apr 2026